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Abstract 
Background: Heart Failure (HF) has been considered the leading cause of hospital readmission 
for patients 65 years of age and older. A pre-discharge B-type natriuretic peptide has been shown 
to be a strong predictor of hospital readmission and mortality according to the American Heart 
Association 2017 Heart Failure Guidelines. A study established a pre-discharge BNP level 
benchmark at 350 pg/ml for optimal outcomes and decreased readmission rates. This benchmark 
recommendation was amended to 450 pg/ml in 2015 from a level 2 systematic review due to the 
better predictive quality of readmission at this revised level. The annual cost for admission of 
patients with HF is greater than $17 billion. Diagnosed heart failure patients continued to be 
discharged without the physician knowing their current BNP levels. The Affordable Care Act 
established the Hospital Readmissions Reduction Program (HRRP) requiring the Center for 
Medicare and Medicaid Services (CMS) to reduce reimbursement to hospitals with high 
readmission rates. The cost of a BNP level is minimal compared to the cost of hospital 
readmission.  
Objective: The purpose of this DNP project included (1) incorporating AHA 2017 guidelines to 
require a pre-discharge BNP level be drawn and evaluated by the PCP, (2) implementing an 
evidence-based protocol incorporating pre-discharge BNP levels be drawn and evaluated to 
reduce 30-day hospital readmission rates, and (3) improving healthcare outcomes for HF patients 
through the reduction of 30-day readmission to hospital facilities. 
Design Method: A needs assessment was completed through a retrospective chart audit to obtain 
BNP levels pre-discharge and on readmission over a two to the three-month timeframe. A second 
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audit was done to evaluate the success of implementing the protocol criteria and assess the 
impact on 30-day readmission rates.  
Project Implementation: The retrospective chart audit needs assessment was completed over a 2-
3-month timeframe. BNP levels were obtained pre-discharge and on readmission. The physician 
group which managed the BNP levels and HF diagnosis were noted. A protocol change was 
initiated by the regional cardiology practice at the audited hospital and they agreed to have their 
hospital cardiology PCP order pre-discharge BNP levels be drawn within 24-48 hours of 
discharge on all of their patients with a primary or secondary diagnosis of HF. A second chart 
audit was performed noting the pre-discharge BNP, whether the BNP was done within the 
designated timeframe, the physician, and the BNP on readmission within 30 days.  
Conclusion: Results showed that the higher the pre-discharge BNP the higher the hospital 
readmittance within 30-days of discharge. When the protocol criteria were not met, a higher 
percentage of readmittance within 30-days occurred compared to when the protocol criteria were 
met. As the pre-discharge BNP rose, the readmittance within 30-days increased and when the 
protocol was implemented the readmittance decreased to approximately 38%. 
Implications for Nursing: The implications of implementing the proposed protocol for a pre-
discharge BNP within 24-48 hours prior to discharge are that 30-day readmission rates will 
decrease which will increase CMS reimbursement to the facility. 
 
Keywords: Pre-discharge BNP, hospital readmission, Heart Failure
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Pre-discharge BNP: A Protocol Change to Reduce Hospital Readmission 
Introduction 
The prevalence of heart failure (HF) has grown due to a longer life expectancy, the aging 
population, the improved survival rate after cardiac occurrences, and the progress that has 
occurred in all areas of medicine (Di Marca et al., 2018; Magnussen & Blankenberg, 2018). The 
leading cause of hospital readmission for patients 65 years of age and older is HF (Yancy et al., 
2017). New HF guidelines were presented in 2017 by the American College of Cardiology and 
the American Heart Association. The utilization of B-type natriuretic peptide (BNP) as a 
predictor of hospital readmission was recommended by this task force (Yancy et al., 2017). The 
usage of BNP levels to reduce readmission has been underutilized in the local hospital setting. 
Although BNP levels have been ordered on a routine basis per national treatment guidelines, 
their full potential for disease management has been underutilized (Wettersten & Maisel, 2016). 
Background 
The annual Medicare expenditure cost for admission of patients with HF is greater than 
$17 billion according to the American Heart Association Statistic Committee (Desai & 
Stevenson, 2012). BNP has been established as an important biomarker in the diagnosis and 
treatment of HF (Schreiber, 2016). BNP levels are obtained through lab draws. A biomarker is 
defined as “A biologic feature that can be used to measure the presence or progress of  disease or 
the effects of treatment” (MedicineNet website, 2018). 
Patients are admitted to the hospital with clinical manifestations of the HF disease 
process and their BNP levels are checked and found to be elevated. The BNP upper level 
diagnostic for HF is > 100 pg/ml (Wettersten & Maisel, 2016). Once the diagnosis is made, 
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medical interventions are prescribed and implemented and patient improvement occurs. These 
interventions include treatment with angiotensin-converting enzyme inhibitor (ACEI) and 
angiotensin receptor blocker (ARB), evidence-based specific beta-blockers, and diuretics 
(American Heart Association [AHA], 2013). As most patients progress, improvement in serial 
BNP levels occur and there is a decline from severe levels, >400 pg/ml, to mild-moderate levels, 
200 pg/ml-400 pg/ml throughout therapy (Mayo Clinic, Mayo Medical Laboratories, 2018). 
Even with prescribed therapy, all patients are not going to respond with a decreased BNP 
level <450 pg/ml prior to discharge. Some patients who had a predischarge BNP level <450 
pg/ml, will have an event that causes them to be readmitted within 30 days of discharge. The 
AHA studies do indicate that patients with BNP levels which are higher during hospitalization 
and do not decline or have a higher predischarge BNP level have worse outcomes (Yancy et al., 
2017). A clinical problem occurs when the last BNP level is drawn several days prior to 
discharge and still indicates moderate to high elevation. According to a level 1 evidence-based 
clinical guidelines, another BNP level should be ordered, and evaluated by the patient care 
provider (PCP) prior to discharge; but this predischarge screening and evaluation of the BNP are 
not occurring (Yancy et al., 2017). 
Diagnosed HF patients continue to be discharged without the physician knowing and 
evaluating their current BNP levels. A clinical problem of hospital re-admission of patients with 
diagnosed HF has been recognized. The new 2017 AHA HF guidelines recommend a pre-
discharge BNP level be drawn. This is not happening in all medical facilities. A change in the 
protocol should be initiated to include a pre-discharge BNP level be drawn on every HF patient 
and presented to the physician prior to discharge.  Recommendations obtained from previous 
PRE-DISCHARGE BNP: A PROTOCOL CHANGE TO REDUCE 10 
 
 
studies related to a timeframe for this BNP level is 24-48 hours prior to discharge (Check, 2004; 
Kociol et al., 2011). 
Problem Statement 
The population of interest for this project is the adult population. HF is a common and 
costly diagnosis for adults 65 years of age and older. Elevated pre-discharge BNP levels have 
been shown to be highly predictive of hospital readmission. The PICOT question for this project 
is as follows: In adult hospitalized Heart Failure patients (P), is an assessment of pre-discharge 
BNP levels (I) as compared to the intermittent drawing of BNP levels (C) more accurate in 
predicting hospital re-admission rates (O) within 30 days of discharge (T)? The Affordable Care 
Act established the Hospital Readmissions Reduction Program (HRRP) requiring The Center for 
Medicare and Medicaid Services (CMS) to reduce reimbursement to hospitals with high 
readmission rates for each of the six program measures.  The six program measures include acute 
myocardial infarction (AMI), pneumonia, chronic obstructive pulmonary disease (COPD), 
coronary artery bypass graft (CABG) surgeries, and elective primary total hip and/or total knee 
arthroplasty (THA/TKA), and HF patients (Centers for Medicare and Medicaid Services [CMS], 
2018). In this project, a retrospective chart audit was utilized in addition to a summary of 
appraised evidence. Internal evidence and evidence synthesized from the literature were 
presented to recommend a hospital protocol change which incorporated drawing a BNP level 
prior to discharge. A BNP range was recommended as criteria for discharge with the 
understanding that any patient-specific modifications needed to individualize care would be 
addressed by the attending physician. This is expected to improve reimbursement by reducing 
readmission rates of HF patients. 
PRE-DISCHARGE BNP: A PROTOCOL CHANGE TO REDUCE 11 
 
 
Organizational Description of Project Site 
In a prior level 5 retrospective observational study, data from 63,678 patients with a 
diagnosis of HF showed that the annual Medicare reimbursement costs were significant. These 
costs were compounded by high hospital readmission rates with 30-day readmission rates 
reported to be greater than 20% (Kilgore, Patel, Kielhorn, Maya, & Sharma, 2017; O’Connor, 
2017). The CMS program was developed and hospitals were required to implement this program 
to improve patient outcomes by lowering readmission rates while lowering costs of treatment 
related to hospital readmissions. To maximize reimbursement, steps must be taken by hospitals 
to reduce these readmission rates. The site for this project was a regional medical center in the 
southeastern United States. Permission for this project was obtained from the Chief Executive 
Officer (CEO) and Chief Nursing Officer (CNO). This doctor of nursing practice (DNP) student 
worked with the Chief Quality Officer (CQO) and a regional cardiology practice to incorporate 
the proposed protocol change. 
Review of Literature 
Reimbursement and hospital performance measures are impacted by the readmission of 
HF patients within 30 days from discharge. These rates have shown a slight decrease in recent 
years but continue to be unacceptably high, as much as 1 in 5 patients (Davis et al., 2017). The 
rate of HF diagnosis is expected to increase 46%-50% by 2030 (Davis et al., 2017; Magnussen & 
Blankenberg, 2018; Mozaffarian et al., 2015). 
The new 2017 American Heart Association (AHA) HF level 1 evidence-based clinical 
guidelines recommend a pre-discharge BNP be drawn. This pre-discharge biomarker, as well as 
the noted BNP level changes during hospitalization treatment, are strong predictors of hospital 
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readmission and mortality (Leto, Testa, and Feola, 2015; Yancy et al., 2017). Feola, et al (2016) 
confirmed the predictive ability of BNP on re-admission. The authors of this study described the 
importance of using BNP as a predictor of adverse outcomes and how this led to better allocation 
of resources and specific tailoring of follow-up care for these HF patients. 
In terms of mortality, BNP is described as the gold standard of prognostic prediction of 
HF and testing this biomarker independently is predictive of survival. This study demonstrates 
that the six-month survivors had a 30% decrease in their BNP levels during hospitalization 
(Lourenco, Ribeiro, Pintalhao, Silva, & Bettencourt, 2015). Di Marco et al. (2018) and Leto, 
Testa, & Feola (2015) found that BNP levels could be utilized to guide therapy in the hospital 
setting and predict short-term mortality and rehospitalization in patients that are diagnosed with 
HF as a secondary diagnosis after admission. They discovered that BNP levels >600 pg/ml had a 
significant negative effect on thirty-day mortality and 3-month readmission rates. 
There is no definitive threshold set for pre-discharge BNP levels in level 1 current 
clinical guidelines within the United States or Europe, although it is agreed that obtaining a pre-
discharge BNP lowers readmission rates and mortality (Agency for Healthcare Research and 
Quality [AHRQ], 2014; Cowie, 2014). This biomarker is considered a noninvasive technique for 
obtaining information about a diagnosis, prognosis, and management. Every 100 pg/ml increase 
in BNP level is associated with a 35% elevation in mortality rate. This same level 2 systematic 
review study declared that a pre-discharge BNP is a stronger predictor of a post-discharge 
outcome and indicator of appropriate treatment strategies than a baseline BNP (Chow et al., 
2017). 
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Findings of Di Somma, Magrini, & Ferri (2011) concurred with a prior level 3 cohort 
study by Logeart et. al (2004) regarding establishing a pre-discharge BNP level benchmark at 
350 pg/ml for optimal patient outcomes and decreased readmission rates. As the pre-discharge 
BNP level rises, the risk of readmission and mortality increases. This benchmark 
recommendation was amended to 450 pg/ml in 2015 from a level 2 systematic review due to the 
better predictive quality of readmission at this revised level (Cohen-Solal et al., 2015). The 
Logeart et al. (2004) study declared a level >700 pg/ml as associated with a major risk of 
readmission and mortality.    
Davis et al. (2017) in a level 3 retrospective cohort study determined that 33.1 % of the 
30-day readmission patients within their study had a previous admission, within the prior two 
years, with HF as a secondary diagnosis. They also concluded that the risk of readmission is 
elevated immediately after discharge and this is true for patients both older and younger than 65 
years of age. These authors believe that guidelines can be set to utilize BNP levels to 
individualize care and guide interventional treatment with more research. 
Evidence suggests that a pre-discharge BNP is predictive of hospital readmission within 
30 days and increased mortality within one year. Utilizing BNP levels to guide care and manage 
treatment can positively impact clinical outcomes. Decreasing 30-day readmission rates allows 
for continued reimbursement through CMS to hospitals and acute care facilities. 
Evidence-Based Practice: Verification of Chosen Option 
To translate this evidence into practice, a hospital protocol change was indicated to 
improve outcomes for HF patients. This protocol would mandate a pre-discharge BNP biomarker 
be drawn and the BNP level reported to medical staff within 24-48 hours prior to discharge. A 
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pre-discharge BNP recommendation of  <450 pg/ml was given due to the predictive nature of 
better outcomes at this level than higher levels according to practice recommendations appraised 
as a level 2 evidence in a systematic review (Cohen-Solal et al., 2015). 
Theoretical Framework 
Everett Rogers developed the diffusion of innovations theory in 1962 and it is one of the 
oldest social science theories. Its utilization in healthcare has grown over the past years. This 
theory illustrates that the adoption of new ideas is a process in which some people are more apt 
to adopt than others (Boston University Medical Campus [BUMC], 2016). This theory is very 
useful in planning an organizational change related to evidence-based practice (EBP) (Melnyk & 
Fineout-Overholt, 2015). The utilization of this theory in EBP has helped to advance innovation 
adoption in clinical practice. The spread of EBP is dependent on early adoption of ideas. The 
diffusion of innovation theory is a framework for this process (Mohammadi, Poursaberi, & 
Salahshoor, 2018). Rogers’ theory took into consideration aspects of the innovation, 
communication styles, decision-making steps, and social background. 
Diffusion is defined by Rogers as communication of new knowledge to a group of 
people. This communication process is initiated through the dissemination of discovered 
knowledge. Through communication, a mutual understanding of how to utilize the new 
knowledge is agreed upon (Peterson & Bredow, 2017). The term innovation refers to new ideas 
and thoughts. Innovation also involves the changing of attitudes regarding new ideas (Lien, 
2017). 
The innovation development process must occur first. Rogers defined five steps in this 
process. The first step is an awareness which occurs when a need for change is discovered. The 
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next three steps are interest, evaluation, and trial. These steps occur when information is gathered 
and a detailed plan is formulated. The final step is the adoption of the new innovation (Peterson 
& Bredow, 2017). 
A synopsis of the 2017 AHA HF guidelines regarding pre-discharge BNP levels as a 
predictor of readmission was presented to the DON at a regional medical center in the 
southeastern United States. The need for a protocol change within the hospital to include pre-
discharge BNP levels be drawn on all HF patients within 48 hours of discharge was discussed. A 
plan was formulated to gather information and studies supporting this claim and present to the 
CQO. During this DNP project, adoption of the need for a protocol change was expected to 
occur. 
Rogers coined the phrase innovation-decision process and determined there were five 
phases (see Appendix A). The initial phase is this newly discovered knowledge. Persuasion is the 
second phase. The advantages of the innovation are presented. The value of the idea is evaluated 
and subsequently, a decision is made which constitutes the third phase. The fourth phase is the 
implementation of the idea. This may occur at varying rates based on the situation. New 
information may need to be investigated. The fifth and final phase is confirmation. Confirmation 
occurs when the decision is made to continue with the innovation (Agency for Clinical 
Innovation [ACI], 2015) (BUMC, 2016). 
During this project, these five steps of the innovation-decision process occurred. The 
knowledge of a pre-discharge BNP level being predictive of 30-day readmission rates for HF 
patients was presented to the adopters and the proposed protocol was revealed. The advantages 
of adopting this protocol were disclosed. These advantages included improving patient care 
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outcomes and increasing hospital reimbursement when a reduction of 30-day readmission rates 
in HF patients was achieved. Education was provided to the PCP, so they could be informed on 
the predictive quality of pre-discharge BNP levels. Face-to-face communication was considered 
the best form of relaying information where a decision of buy-in needs to occur. This allows the 
advocate (DNP student) the opportunity to individualize the communication based on the 
identified adopter categories regarding why the shift in clinical behavior needed to occur 
(Swanson-Fisher, 2004). This was reinforced through the presentation of the 2017 AHA 
guidelines for HF. Once the protocol change was incorporated into the routine care of HF 
patients in the regional cardiology group, another retrospective chart audit was performed and 
data collected regarding the reduction in HF readmission rates of the regional cardiology group 
versus the other physicians at this facility. This was presented to the adopters comparing 30-day 
readmission rates pre- and post-protocol change. Groups and individuals progressed through this 
decision process at different speeds based on their adopter category (Swanson-Fisher, 2004).  
Rogers believed that people involved in a change must make a decision to accept or reject 
the proposed change. There are certain characteristics which influence this change. These 
intrinsic characteristics include relative advantage, compatibility, degree of complexity, 
trialability, and observability. Relative advantage refers to the ability to see the change as an 
improvement. Compatibility describes the ability to integrate the innovation into policy. 
Anticipated issues with whether to adopt or use the innovation are referred to as the degree of 
complexity. Trialability is the available chance to test or experiment with the innovation, and 
observability means there is an opportunity to communicate the positive and negative reactions 
to the innovation (ACI, 2015; BUMC, 2016).  Each of these characteristics must be addressed 
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within the protocol education to positively influence buy-in of the adopters. The adoption of a 
new innovation is more likely to occur if there is an advanced rate of perceived advantage, 
compatibility, trialability, and observability and have reduced levels of complexity (Peterson & 
Bredow, 2017). 
Identification of how adopters reacted to change due to innovation in past experiences 
can lead to a determination of the best strategies to utilize in influencing adopters to accept 
change (Lien, 2017). There are five adopter categories identified in Rogers’ Diffusion of 
Innovation theory (see Appendix B). The first category is the innovator. Innovators often 
develop new knowledge and are the first to try the innovation. The second category is comprised 
of what Rogers referred to as early adopters. Early adopters embrace change opportunities 
because they already recognize the need for change and are very comfortable with new idea 
innovation. The next category is called the early majority. Whereas early adopters are often 
leaders, the early majority rarely are. The early majority will adopt change quicker than the 
average person, but they need evidence that the innovation is effective (BUMC, 2016; Melnyk & 
Fineout-Overholt, 2015). 
The late majority is another category. This group is unsure of change and reluctant to 
change until the innovation has already been utilized effectively by the majority of people. 
Laggards encompass the final category and are very conservative and reluctant when it comes to 
change. They are the most difficult group to have embrace change (BUMC, 2016). In time, 
laggards will adopt new innovation once it becomes standard practice. It is most important to 
target innovators and early adopters because they will be active in the facilitation of 
organizational change (Melnyk & Fineout-Overholt, 2015). 
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It is imperative to understand strategies to deal with each adopter category. No action 
needs to be taken to get the support of individuals in the innovator group. The early adopters are 
not resistant to change. Education through how-to manuals and information sheets provides the 
encouragement they need for adoption. Early majority groups need information provided on the 
effectiveness of the change and success stories from the adoption of the change in other facilities. 
Individuals in the late majority group must be influenced to adopt change by hearing examples of 
how other people adopted the innovation successfully. Laggards are the hardest group to 
influence to adopt change. This population relies strictly on statistical data and pressure from 
other adopter groups (BUMC, 2016). It is key to determine the adopter category of the people 
with whom you are working on this new innovation. Once that is determined, the focus must 
then be concentrated on strategies to influence the adoption and support of new innovations.  
The Diffusion of Innovation theory has been applied in multiple healthcare situations to 
determine how the innovation of new information or strategies are translated into current clinical 
practice (Lien, 2017). Strategies have been developed to support innovation implementation. 
Education provided in a practice setting by a peer is more likely to yield a positive result in 
changing provider prescribing and ordering practices. Reminders should be provided to reinforce 
the innovation. Reinforcement needs to occur to prevent the adopter from discontinuing the 
usage of the innovation (Peterson & Bredow, 2017). The adoption of evidence-based practice is a 
major factor in improving healthcare outcomes (Swanson-Fisher, 2004). The gaps between 
evidence-based practice and current care can be bridged using Rogers’ Diffusion of Innovation 
theory and best evidence translated to practice effectively. 
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Goals, Objectives and Expected Outcomes 
The goal of this project was to establish a protocol change to incorporate a pre-discharge 
BNP level be drawn on all patients with a primary or secondary diagnosis of HF. This is a 
current recommendation by the AHA based on new observational studies. These level 1 HF 2017 
guidelines established a pre-discharge BNP level as useful in discharge prognosis (Yancy et al., 
2017). Yancy et al. (2017) observed that pre-discharge BNP levels had a higher discrimination 
and predictive value than clinical variables in anticipating poor outcomes and readmission rates.  
The objectives for this DNP project included (1) incorporating AHA 2017 guidelines to 
require a pre-discharge BNP level be drawn and evaluated by the PCP, (2) implementing an 
evidence-based protocol incorporating pre-discharge BNP levels be drawn and evaluated to 
reduce 30-day hospital readmission rates, and (3) improving healthcare outcomes for HF patients 
through the reduction of 30-day readmission to hospital facilities. These objectives were 
implemented by the regional cardiology practice at the regional medical center and carried out by 
the cardiology patient care providers and hospital acute care nurses. The objectives led to the 
formation of a hospital protocol to obtain the pre-discharge BNP level within 24-48 hours prior 
to discharge, with a BNP recommendation of <450 pg/ml at the time of discharge (see Appendix 
C). 
The expected outcome of this project was the creation and approval of a protocol change 
requiring BNP levels be drawn within 24-48 hours prior to discharge for HF patients, which will 
ultimately lead to a practice change and a reduction of hospital readmissions of HF patients 
within 30 days of discharge. This has become an important goal for hospitals due to the 
construction of the HRRP which was established by the federal government in 2012 to reduce 
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hospital readmissions by impacting reimbursement to hospitals with excess readmissions. This is 
a pay-for-performance program which links reimbursement to the quality of hospital care. 
Each of the six program measures, which includes HF, are evaluated for excess readmission 
ratios (ERRs) (Centers for Medicare and Medicaid Services [CMS], 2018). This strong financial 
incentive has a positive influence on care coordination.  
Project Design 
The aim of this project was the creation of a written protocol change to incorporate the 
drawing of a pre-discharge BNP level for utilization in discharge criteria for HF patients. A 
needs assessment was completed through a retrospective chart audit to obtain BNP levels pre-
discharge and on readmission over a two to three-month timeframe (see Appendix D). The 
physician/physician group which managed the BNP levels and HF diagnosis were noted. These 
levels were collected on patients diagnosed with HF and readmitted within 30 days of discharge. 
The collected data was not linked to specific patients’ demographic data. Data obtained was 
presented to the CQO and regional cardiology practice to demonstrate evidentiary support for a 
protocol change to incorporate pre-discharge BNP levels be drawn within 24-48 hours prior to 
discharge (Check, 2004; Kociol et al., 2011). 
The regional cardiology group had their cardiology hospital patient care providers to 
order the pre-discharge BNP level on all patients with a primary or secondary diagnosis of HF 
within 24-48 hours prior to discharge. A second data collection was completed by the DNP 
student through another retrospective chart audit of patients with a diagnosis of HF to determine 
if the BNP was obtained within 24-48 hours pre-discharge per protocol requirements and 
whether the patient was readmitted within 30 days (see Appendix E). The physician/physician 
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group managing the BNP and HF was noted. This showed if the protocol implementation was 
successful and the impact it had on 30-day readmission rates of HF patients for this regional 
cardiology practice compared to the physician/physician groups which did not implement this 
proposed protocol change. This evidentiary data was presented to the CQO, the regional 
cardiology practice, and medical staff to obtain support for the proposed protocol change. A BNP 
level <450 pg/ml was proposed prior to discharge to optimize outcomes (Cohen-Solalet al., 
2015; Logeart et al., 2004). 
Project Site and Population 
This project took place at a regional medical center in the southeastern United States. The 
patients included in the retrospective chart audit needs assessment were comprised of adult 
patients with a primary or secondary diagnosis of HF on any Medical-Surgical floor or Intensive 
Care Unit who were readmitted within 30 days of a prior discharge. The data collected was not 
linked to specific demographic data that could be used to identify the patient. The 
interprofessional collaborative process occurred with the CQO and regional cardiology practice 
to appraise the evidence regarding BNP levels drawn at the time of discharge, made a 
recommendation for practice at the regional medical center, and composed a protocol to meet the 
criteria stated above. 
Setting facilitators and barriers. Facilitators, in terms of driving forces for this project, 
were the results of an internal needs assessment identifying HF patient readmission rates and the 
CMS guidelines which dictate a reduction of hospital reimbursement for services to HF patients 
who were readmitted within 30-days post-discharge. Barriers to this project included resistance 
by hospital administrators, cardiologists, and medical staff who opposed implementing the 
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protocol change. Evidence was presented to the CQO and the regional cardiology practice to 
garner support for this protocol change. 
Implementation Plan/Procedures 
A timeline of project implementation was created (see Appendix F). Contact was made 
with the Director of Nursing concerning the DNP project plan. Permission was obtained from the 
hospital where the project took place and from the regional cardiology group that implemented 
the practice of ordering and having pre-discharge BNP levels drawn during this project. Data 
collection for a needs assessment was gathered through a retrospective chart audit of all patients 
with a primary or secondary diagnosis of HF readmitted within 30 days of discharge. The data 
obtained from this internal needs assessment included data not linked to identifying patient data 
(see Appendix D). 
The CNO appointed the CQO to assist this DNP student with this project. The CQO and 
members of the regional cardiology practice adopter category were determined to be early 
adopters through discussion. The CQO and regional cardiology practice were provided the 
collected data and a literature review of appraised evidence with a summarized synthesis of that 
evidence regarding the correlation between elevated BNP levels at the time of patient discharge 
and hospital readmission by the DNP student. Through interprofessional collaborative efforts, 
the regional cardiology practice agreed to have their hospital cardiology PCP order pre-discharge 
BNP levels be drawn within 24-48 hours of discharge on all of their patients with a primary or 
secondary diagnosis of HF. Data was presented to the CQO, the regional cardiology group, and 
the medical staff. This data was utilized to write a protocol to include a pre-discharge BNP level 
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be drawn within 24-48 hours of discharge for all patients with a primary or secondary diagnosis 
of HF. 
Measurement Instruments 
Hospital readmission is costly and is considered indicative of poor-quality hospital care. 
HF is a common and severe disease process which is associated with increased readmission. The 
tracking of readmission rates is performed by case management at this facility. This tracking is 
more of a process. A daily report lists readmission rates for specific diagnoses. These are 
identified through coding specific for the disease process and are placed on a spreadsheet. Then 
it is accessed by the QI office.  
A tool was developed by the DNP student to utilize for the retrospective chart audit needs 
assessment (see Appendix C). This tool includes the patient’s admission date and discharge date, 
the date of the last BNP level drawn prior to discharge, the numeric value of the last BNP level 
drawn prior to discharge, the physician/physician group managing the patient’s BNP, the date of 
readmission, and the numeric BNP level on readmission. No identifying patient data was utilized 
that could be linked to a particular patient.  
A second tool was developed to evaluate the effectiveness of the protocol implementation 
(see Appendix D). This data was obtained through another retrospective chart audit which was 
not linked with any patient identifiers. It included the date the final BNP was drawn and whether 
that was within 24-48 hours prior to discharge or longer than 48 hours prior to discharge. It also 
included the physician/physician group managing the HF and the BNP on readmission.  
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Data Collection Procedures 
Once permission was obtained from the hospital, data collection through a retrospective 
chart audit for needs assessment of BNP levels was initiated. A retrospective chart audit was 
utilized to gather data on BNP levels of patients readmitted within 30 days of discharge from a 
prior admission with HF being a primary or secondary diagnosis. No other private health 
information was accessed. The data collected included the patient’s admission date and discharge 
date, the date of the last BNP level drawn prior to discharge, the numeric value of the last BNP 
level drawn prior to discharge, the physician/physician group managing the patient’s BNP, the 
date of readmission, and the numeric BNP level on readmission. This acted as a needs 
assessment to illustrate the necessity for a pre-discharge BNP to be drawn within 48 hours prior 
to discharge. These BNP levels were utilized to demonstrate the need for a pre-discharge BNP to 
be drawn and showed how it was predictive of a 30-day readmission. 
Collaboration with the CQO occurred in writing a hospital protocol. The EBP process 
began with the determination of a clinical problem. The PICOT question was then formulated 
and the search for the best evidence began. As the evidence was discovered, a critical appraisal 
of that evidence occurred (Melnyk & Fineout-Overholt, 2015). These steps and their results were 
presented to the CQO and regional cardiology practice in an evidence synthesis table. The 
evidence appraisal from the literature and the internal needs assessment were utilized to educate 
these clinicians on the importance of this clinical problem and the reliable evidence to support a 
recommended protocol change in clinical practice. The CQO and DNP student worked 
collaboratively to synthesize the evidence and collected data to write an appropriate evidence-
based protocol (appendix D) to improve HF patient outcomes after a hospital discharge.  
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This protocol was inclusive of drawing a pre-discharge BNP level on all patients with a 
primary and secondary diagnosis of HF within 48 hours prior to discharge. Evaluation of the 
number of admitted HF patients with the BNP drawn within 24-48 hours prior to discharge was 
compared to patients who did not have a pre-discharge BNP level drawn. The presentation of the 
collected data related to BNP drawing pre-protocol change and the evaluation of data collected 
regarding BNP  drawing post-protocol change were compared. This demonstrated the impact of 
adherence to the proposed protocol. 
The guideline on the recommendation from the AHA HF guideline document was added 
to this comparison so patient care providers and acute care medical/surgical nurses understood 
the need for this evidence-based protocol change. The need for the protocol change was 
illustrated through this comparison. Improved patient care outcomes will encourage early 
majority, late majority, and laggards to embrace and support this protocol change. The benefit of 
the translation of evidence into practice will be apparent by the reduction of the evidence-
practice and policy gap which exists globally in clinical practice and the healthcare field 
(Grimshaw, Eccles, Lavis, Hill, & Squires, 2012). Utilization of research evidence is imperative 
to improving clinical outcomes. 
Data Analysis 
The data collected through the initial retrospective chart audit was analyzed utilizing 
quantitative, descriptive statistical analysis. After the protocol was utilized by the regional 
cardiology group, quantitative, descriptive statistics were collected through analysis of the 
second retrospective chart audit. This comparative assessment demonstrated the effectiveness of 
the pre-discharge BNP policy. 
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Cost-Benefit Analysis/Budget 
Utilization of the 2017 AHA HF guidelines to decrease hospital readmission of HF 
clients is an important initiative. According to a level 5 expert opinion study, the annual cost for 
admission of patients with HF is greater than $17 billion (Desai & Stevenson, 2012). In 2011, 
134,500 patients were readmitted with this diagnosis. It is the most common condition noted in 
Medicare hospital readmission data (Stuart, 2014). The Heart Disease and Stroke Statistic Report 
(2016) details an estimated one million hospital stays were due to HF. The AHA reports that 
treatment costs for HF are expected to rise to $53 billion by 2030 (Chamberlain, Sond, 
Mahendraraj, Lau, & Siracuse, 2018). HF-related hospitalization expenses have risen to an 
average per-patient cost of $14,631 per hospitalization with an average stay of 5 days. A single 
HF patient’s inpatient care is estimated at $83,980 throughout their lifetime (Kilgore, Patel, 
Kielhorn, Maya, & Sharma, 2017). 
Medical facilities are penalized by withholding reimbursement for readmission of HF 
clients within 30 days of discharge. A BNP level costs anywhere from $78 to $205 depending on 
which lab the test is ordered from (Quest Diagnostics, 2017). This cost is minimal compared to 
the cost of a hospital readmission for HF. The usage of this laboratory test to prevent a costly 
readmission is essential in the quest to deliver high quality, patient-centered care at a reduced 
financial impact on the healthcare system. 
Timeline 
A proposed timeline was composed to map out the steps for this DNP project to begin in 
July 2018 and be completed April 2019 (see Appendix F). Permission was obtained in July of 
2018 from the CNO to utilize the proposed hospital facility for this project. Evidence-based data 
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was obtained to present to the CNO and CQO to support the need for the proposed protocol 
change. In September, a meeting with the CNO occurred to discuss the project plan and timeline. 
The CQO met with this DNP student to discuss the collection of data and evidence in support of 
a protocol change in November. Initial BNP data were collected through a retrospective chart 
audit to present to the regional cardiology group and CQO and to utilize for comparison with 
data collected at the end of the project. 
At the beginning of 2019, the proposed protocol was implemented through the regional 
cardiology group. Throughout the process of implementation with the regional cardiology group, 
adopters were identified and categorized. The effectiveness of the implementation of the pre-
discharge BNP protocol was evaluated through April of 2019. The chart audit data was collected 
throughout that timeframe, compiled, analyzed, and then presented to the CQO, regional 
cardiology group, and the medical staff to gain support for this evidence-based protocol change. 
This protocol was developed and written through interprofessional collaboration. The 
presentation of the literature review and analyzed data demonstrated the need for the protocol 
change and the effectiveness of the implementation of the pre-discharge BNP protocol. The 
impact on potential improved patient outcomes and subsequent potential HR reimbursement by 
CMS was evident. 
Ethical Considerations 
The Jacksonville State University Institutional Review Board (IRB) approval was 
obtained before initiating the DNP project. This project utilized a retrospective chart audit to 
collect pre-discharge BNP data on discharged HF patients and showed a needs assessment for 
protocol change. No patient interaction occurred and no Protected Health Information (PHI) was 
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recorded except date of admission and discharge, date and the numeric value of pre-discharge 
BNP, the physician/physician group managing the HF diagnosis, date readmitted and numeric 
BNP level on readmission. The second chart audit was not linked to any PHI and only evaluated 
the effectiveness of the implementation of the protocol by recording the date the BNP was drawn 
prior to discharge and whether that was within 24-48 hours prior to discharge or earlier than that. 
The individual physician or cardiology group managing the HF diagnosis was also noted. 
There are minimal risks associated with the collection of this data or the implementation 
of this project. The most significant risk is that the data was not collected and that patient care 
providers did not follow the implemented protocol. Benefits of this project included improved 
patient care outcomes due to the implementation of this protocol. Increased reimbursement by 
Medicare to the facility due to a reduction in 30-day readmission rates is a significant benefit. 
Conclusion 
The prevalence of HF diagnosis is increasing annually and it is a very costly diagnosis. 
Criteria for CMS reimbursement on HF patients is based on reduction of 30-day hospital 
readmission rates. It has been established nationally that BNP levels are not being assessed 
within 24-48 hours prior to discharge on hospitalized HF patients and the 2017 AHA HF Clinical 
Guidelines state that pre-discharge BNP levels are highly predictive of hospital readmission 
within 30 days of discharge (Leto, Testa, & Feola, 2015; Yancy et al., 2017).  A level 2 
systematic review in 2015 set a benchmark BNP recommendation at 450 pg/ml due to its strong 
predictive quality for readmission at greater levels (Cohen-Solal et al., 2015). Evidentiary 
support from the literature indicates the need for the pre-discharge BNP to be drawn within 24-
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48 hours prior to discharge for best predictive assessment of readmission (Check, 2004; Kociol 
et al., 2011).  
The initial needs assessment was completed through a retrospective chart audit at a 
regional medical center in the southeastern United States between September and 
December. This retrospective chart audit of HF patients originally admitted with a primary or 
secondary diagnosis of HF were all patients that readmitted within 30 days of discharge. Of these 
20 patients managed by various physicians, 85% had a pre-discharge BNP >450 pg/ml. Also, 
85% had a lower pre-discharge BNP than their BNP on readmission. The regional cardiology 
group was the physician group managing the HF diagnosis for 45% of the patients on this initial 
retrospective chart audit. The other 55% of the patients in this retrospective audit were managed 
by other cardiologists and physician groups. 30% of these patients in this audit did not have a 
pre-discharge BNP drawn within 24-48 hours of discharge. This data verified that a positive 
impact would occur in patient care with the implementation of a pre-discharge BNP protocol to 
increase awareness of this biomarker lab level within 24-48 hours prior to discharge. 
A regional cardiology group practicing at the audited regional hospital instructed their 
PCP within the hospital to order pre-discharge BNP levels within 24-48 hours prior to discharge 
on all patients with a primary or secondary diagnosis of HF. During a two to three-month time 
frame, 88% of this cardiology group’s HF patients did have a pre-discharge BNP drawn within 
24-48 hours of discharge. 
A second chart audit was performed by this DNP student to determine the success of 
implementing the protocol criteria by this regional cardiology group and the impact it had on 
their 30-day readmission rates for HF patients. This data was collected between January and 
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March. Fifty-seven patients managed by various physicians were audited and 68% had a pre-
discharge BNP >450 pg/ml which is lower than the initial audit. Of the 32% of patients with a 
pre-discharge BNP < 450 pg/ml, 83% of these HF patients were managed by the regional 
cardiology group that initiated the proposed protocol. 93% of these patients did not readmit 
within 30 days. This was compared to patients who did not have a pre-discharge BNP ordered 
within 48 hours of discharge and showed that 88% had a BNP value of  >450 pg/ml. 63% of 
these patients readmitted within 30 days. This indicates that there was a lower readmission rate 
on HF patients that had a pre-discharge BNP drawn within 24-48 hours prior to discharge than 
on patients that had a BNP drawn outside of 48 hours prior to discharge.  
The contour plots (Appendix H) showed that the larger the pre-discharge BNP the higher 
the hospital readmittance within 30 days of discharge. The contour plot illustrating when the 
protocol criteria were not met indicated that a larger percentage of readmittance within 30 days 
occurred compared to the contour plot displaying when the protocol criteria were met. The main 
effects plot (Appendix I) demonstrated that as the pre-discharge BNP rose the readmittance 
within 30 days increased and that when the protocol was implemented the readmittance 
decreased to approximately 38%. The data and conclusions obtained through the retrospective 
chart audits were presented to the CQO, the regional cardiology group, and the Cardiology 
Steering Committee. 
Implications 
The implications of implementing the proposed protocol for a pre-discharge BNP within 
24-48 hours prior to discharge are that 30-day readmissions will decrease which will increase 
CMS reimbursement to the facility. The facility could also add this to the HF hard stop which 
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would ensure that the protocol order was carried out on all HF patients prior to discharge. The 
process for protocol implementation through the Quality Improvement committee is in progress. 
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Appendix A 
Evidence Synthesis Table 
 
Citation: 
Authors(s), Date 
of Publication & 
Title 
 
 
Conceptual 
Framework 
Design/Method Sample/Setting 
Major 
Variables 
studied (and 
their 
definitions) 
Measurement 
of Major 
Variables 
Data 
Analysis 
Study 
Findings 
Appraisal: Worth 
to Practice 
Agency for 
Healthcare 
Research and 
Quality. (2014). 
Acute heart 
failure: diagnosing 
and managing 
acute heart failure 
in adults. 
Retrieved from 
https://www.guid
eline.gov/summari
es/summary/4875
2/acute-heart-
failure-diagnosing-
and-managing-
None Design: 
Evidence-based 
guidelines. 
- Meta-
analysis 
- Systema
tic 
Reviews 
- Observat
ional 
studies 
Level 1 
evidence 
Purpose- 
Diagnosis and 
N= n/a 
Setting- All 
hospitals 
admitting 
people with 
suspected 
heart failure 
Variables: 
Diagnosis of 
HF- BNP >100 
ng/liter 
 
None None BNP used for 
diagnosis of 
HF. 
Hospitals 
should 
provide a 
specialized 
HF team.  
Input from 
the specialist 
heart failure 
team should 
be provided 
to all 
patients. 
Follow up 
Strengths: 
Appropriate 
management of 
individuals with 
acute heart failure 
Limitations: As 
with any 
diagnostic test, 
there will be false-
negative and 
false-positive 
results in the use 
of natriuretic 
peptide testing. 
Conclusion: A 
strong appraisal of 
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acute-heart-
failure-in-
adults?q=heart+fai
lure 
management of 
heart failure. 
care within 2 
weeks of 
discharge. 
care for HF 
patients. 
 
Chamberlain, R., 
Sond, J., 
Mahendraraj, K., 
Lau, C., & Siracuse, 
B. (2018, April 9). 
Determining 30-
day readmission 
risk for heart 
failure patients: 
the Readmission 
After Heart Failure 
scale. 
International 
Journal of General 
Medicine, 
2018(11), 127-141. 
http://dx.doi.org/1
0.2147/IJGM.S150
676 
None Design: Cohort 
study 
-Univariate  
- multivariate 
Level IV 
evidence 
Purpose: This 
study sought to 
develop a scale 
that reli- 
ably predicts 
readmission 
rates among 
patients with 
CHF 
 
N= 642,448 
patients with 
CHF from 
California and  
New York 
(derivation 
cohort).  
365,359 
patients with 
CHF from 
Florida and 
Washington  
(validation 
cohort)  
Setting: 
patients 
diagnosed 
with CHF. 
Variables:  
RAHF scale: 
Readmission 
after Heart 
Failure scale- 
predicts 
readmission 
rates.  
Readmission 
time: 30 days. 
Demographic 
data: age, 
race, gender, 
length of stay, 
insurance. 
RAHF scale: 
Does the RAHF 
scale accurately 
predict 
readmission 
within 30 days?  
 
-Chi-
square  
-
Univariate 
analysis 
 
The RAHF 
scale reliably 
predicts 30-
day 
readmission 
rates of HF 
patients.  
p= <0.01 
Strengths: quickly 
and accurately risk 
stratify patients 
during the initial  
hospitalization for 
CHF. Enables 
improved coor- 
dination of care 
between 
healthcare 
professionals and 
imple- 
mentation of 
various strategies 
to prevent 
readmissions 
among  
high-risk patients.  
 
 
Limitations: Exact 
HRRP guidelines 
not utilized. 
Limited 
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generalizability 
related to HF 
readmissions 
around the world. 
Readmission risks 
constantly change. 
sampling and 
coding errors, 
misclassified 
variables,  
and the difficulty 
in accurately 
obtaining 
readmission data  
Conclusions: The 
RAHF scale reliably 
predicts a 
patient’s 30-day 
CHF readmission 
risk based  
on demographic 
and clinical factors 
present upon 
initial admission.  
Feasibility: 
strategies tailored 
to each patient 
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can be 
implemented  
to improve patient 
outcomes and 
reduce healthcare 
costs 
Chow, S. L., 
Maisel, A. S., 
Anand, I., Bozkurt, 
B., de Boer, R. A., 
Felker, G. M., ... 
Zile, M. R. (2017). 
Role of biomarkers 
for the prevention, 
assessment, and 
management of 
heart failure: A 
scientific 
statement from 
the American 
Heart Association. 
Circulation, 135. 
http://dx.doi.org/1
0.1161/CIR.00000
00000000490 
None Design: 
Systematic 
review of 
experimental 
studies 
Level 2 
evidence 
Purpose: to 
summarize the 
existing 
literature and to 
provide 
guidance for the 
utility of 
currently 
available 
biomarkers. 
None Variables: IV1: 
BNP. IV2: 
other 
biomarkers. 
DV: provide 
added value 
to medical 
management, 
which could 
potentially 
lower the risk 
of mortality 
and 
readmissions. 
BNP: Can it be 
used to 
medically 
manage HF? 
Other 
biomarkers: 
Should they be 
utilized to 
manage HF 
treatment. 
None Biomarkers 
can provide 
the clinician 
with 
information 
about the 
diagnosis 
and severity 
of HF but 
also can 
improve 
prognosticati
on and 
treatment 
strategies. 
Limitations: a 
need to further 
evaluate existing 
and novel markers 
for guiding 
therapy and to 
summarize their 
data in a 
standardized 
format to improve 
communication 
among 
researchers and 
practitioners. 
 
Strengths: 
systematic 
literature reviews, 
published 
translational and 
clinical studies, 
clinical practice 
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guidelines, and 
expert 
opinion/statement
s were used to 
summarize 
existing evidence 
and to identify 
areas of 
inadequacy 
requiring future 
research. 
 
Conclusion: BNP 
can provide the 
clinician with 
information about 
the diagnosis and 
severity of HF but 
also can improve 
prognostication 
and treatment 
strategies. 
 
Feasibility: Aids in 
answering the 
PICOT question. 
BNP and other 
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biomarkers can 
aid in treatment. 
Cohen-Solal, A., 
Laribi, S., Ishihara, 
S., Vergaro, G., 
Baudet, M., 
Logeart, D., ... 
Seronde, M. 
(2015). Prognostic 
markers of acute 
decompensated 
heart failure: The 
emerging roles of 
cardiac biomarkers 
and prognostic 
scores. Archives of 
Cardiovascular 
Disease, 108, 64-
74. 
http://dx.doi.org/1
0.1016/j.acvd.201
4.10.002 
none Design: 
Systematic 
review- Level 2 
Purpose: that 
could be used 
by the clinician 
when assessing 
outcome in 
patients with 
HF. 
 
None Variables: 
Scoring tools 
for prognostic 
value in heart 
failure.  
Should 
biomarkers 
alone be used 
for prognostic 
value? 
What 
predictors are 
needed to 
provide a 
prognostic 
framework in 
care of HF? 
None Evaluation 
of tools and 
criteria for 
assessing the 
prognosis of 
HF. 
Strengths: 
Compilation of 
many studies. 
Limitations: No 
scoring tool exists. 
Conclusion: 
Outcome 
predictors are 
urgently needed. 
More studies 
should be done 
that include 
biomarkers. 
Cowie, M. R. 
(2014, June 14). 
BNP-guided 
therapy for 
chronic heart 
failure: anything 
None Design: 
Systematic 
review 
Level 2 
Purpose: Should 
NP levels be 
None IV1: Serial 
BNP therapy 
IV2: Clinical 
guidelines 
Should there 
be serial 
management of 
HF using BNP? 
 
None Should serial 
BNP levels 
versus 
current 
clinical 
guidelines 
Limitations: cost 
impact 
Strengths: 
decreased 
mortality 
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more than just an 
attractive 
concept? 
European Heart 
Journal, 35(23), 
1507-1509. 
http://dx.doi.org/1
0.1093/eurheartj/
ehu134 
used to guide 
therapy and 
medical 
treatment.  
DV1: 
Treatment of 
HF 
Are clinical 
guidelines for 
treatment best 
practice in the 
treatment of 
HF? 
be the best 
treatment 
for HF? 
Conclusion: 
clinical guidelines 
are appropriately 
cautious in 
recommending 
BNP-guided 
therapy in routine 
practice at the 
present time. 
A large 
randomized 
clinical trial should 
be performed.  
Davis, J. D., Olsen, 
M. A., Bommarito, 
K., LaRue, S. J., 
Saeed, M., Rich, 
M. W., & Vader, J. 
M. (2017, 
January). All-payer 
analysis of heart 
failure 
hospitalization 30-
day readmission: 
Comorbidities 
matter. American 
Journal of 
Medicine, 130(1), 
None Design: 
Retrospective 
cohort study 
Level 3 
evidence 
Purpose: 
investigated 
readmission 
characteristics 
and the 
magnitude of 
30-day hospital 
readmissions 
after hospital 
discharge for 
N= 547,068 
patients 
Setting: Adults 
aged ≥ 40 
years 
hospitalized 
with a primary 
discharge 
diagnosis of 
heart failure 
from 2007–
2011 were 
identified in 
the California, 
New York, and 
Variables: 
IV1- HF 
readmissions 
IV2- non-HF 
readmissions 
DV: 30-day 
readmissions 
Are 30-day 
readmissions 
primarily due 
to non-HF 
causes? 
Are 30-day 
readmissions 
due to HF 
causes? 
Chi-
square 
Student t-
test 
Wilcoxon’
s test 
 
Did a higher 
percentage 
of HF cases 
readmit for 
HF as a 
primary 
diagnosis or 
Non-HF 
cases? 
Limitations: No 
data more recent 
than 2011. 
Adjudication of 
the primary 
diagnosis versus a 
secondary 
diagnosis as the 
primary reason for 
admission. All data 
were collected 
prior to the 
implementation of 
the Hospital 
Readmission 
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93.e9–93.e28. 
http://dx.doi.org/1
0.1016/j.amjmed.2
016.07.030. 
heart failure 
using the 
Healthcare Cost 
and Utilization 
Project State 
Inpatient 
Databases (SID). 
Florida SIDs. 
How many 
were 
readmitted? 
Reduction 
Program under 
the Affordable 
Care Act. 
Strengths: Bias is 
avoided 
Conclusions: The 
majority of 30-day 
readmissions were 
for non-heart 
failure causes. 
Feasibility: 
Opportunities to 
individualize care 
and guide 
development of 
prospective 
interventions 
designed to have a 
greater impact on 
reducing 
readmissions and 
improving other 
clinical outcomes. 
Desai, A. S., & 
Stevenson, L. W. 
(2012, July 23). 
Rehospitalization 
None Design:  Expert 
Opinion 
Level 5 
N= N/A 
Setting:  
Patients 
readmitted 
IV1: 
Transition 
Phase IV2: 
Plateau Phase 
Should HF 
management 
be redesigned?  
None None Limitations: Only 
opinions. 
Strengths: 
Experience of 
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for heart failure 
predict or 
prevent? 
Circulation, 126(4), 
501-506. 
http://dx.doi.org/1
0.1161/CIRCULATI
ONAHA.112.12543
5 
with HF within 
30 days of 
discharge. 
IV3: Palliation 
and Priorities 
phase  
DV: Reduction 
in 30-day 
readmissions 
experts. 
Conclusions: It is 
not possible to 
adjust fully for the 
measured and 
unmeasured 
individual and 
socioeconomic 
factors that 
contribute to the 
likelihood of 
readmission for 
patients or 
hospitals. 
Feasibility: This 
article discussed 
the management 
of HF and the 
redesign of 
treatment 
regimens. 
Disincentives 
should not be too 
harsh or it could 
negatively impact 
care. 
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Di Marca, S., 
Rando, A., 
Cataudella, E., 
Pulvirenti, A., 
Alaimo, S., 
Terranova, V., ... 
Malatino, L. (2018, 
March 2). B-type 
natriuretic peptide 
may predict 
prognosis in older 
adults admitted 
with a diagnosis 
other than heart 
failure. Nutrition, 
Metabolism & 
Cardiovascular 
Diseases, 28, 636-
642. 
http://dx.doi.org/1
0.1016/j.numecd.2
018.02.017 
None Design: 
Prospective 
controlled trial 
Level 2 
N=404  
Setting: 
consecutive 
patients  
aged≥65 years 
hospitalized 
IV1: BNP >600 
pg/ml; IV2: 
Admission 
diagnosis 
other than HF 
DV: 30-day 
mortality 
after 
discharge 
Will a BNP >600 
along with an 
admission 
diagnosis other 
than HF impact 
30-day 
mortality post-
discharge?  
Logistic 
regression 
analysis 
Logistic 
regression 
analysis in-
hospital 
mortality 
was not 
identified by 
BNP > 
600pg/ml 
but was by 
other 
diagnoses 
other than 
HF.  
Limitations: 
Consecutive 
patients used, not 
randomized. 
Strengths: large 
cohort of patients.  
Conclusion: 
BNP>600 pg/ml, 
CKD, malnutrition, 
and age predict 
thirty-day 
mortality after 
discharge in 
elderly patients 
with an admission 
diagnosis other 
than HF.  
Feasibility: The 
study shows that 
three-month re-
hospitalization 
was predicted by 
BNP>600 pg/ml 
and anamnestic 
HF. 
Di Somma, S., 
Magrini, L., & 
Ferri, E. (2011, 
None Design: 
Literature 
Review 
N= N/A 
Setting: 30-
day and 1-year 
Variables: 
IV1- BNP; IV2- 
NT-ProBNP. 
Does BNP and 
Pro-BNP levels 
predict 
none None Strengths: 
Multiple article 
results included.  
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February 1). In-
hospital brain 
natriuretic peptide 
and N-terminal 
prohormone brain 
natriuretic peptide 
variations are 
predictors of 
short-term and 
long-term 
outcome in acute 
decompensated 
heart failure. 
Critical Care, 
15(116). 
http://dx.doi.org/1
0.1186/cc9970 
Level 5 
evidence 
 
mortality and 
readmission in 
patients  
admitted to 
the emergency 
department 
for acute 
decom- 
pensated 
heart failure  
 
DV1- 
mortality; 
DV2- 
readmission 
mortality and 
hospital 
readmission of 
HF patients? 
Limitations: future  
prospective 
studies need to 
evaluate a distinct 
cut-off 
point  
to allow more 
precise 
recommendations  
 
Feasibility: This 
study looks at the 
ability to use 
these lab tests to 
predict outcomes. 
Conclusions: BNP 
at 24 hours could 
be suitable  
to assess 
prognosis and to 
vary treatment in 
order to decrease 
mortality in 
patients with 
constant elevated  
levels of BNP.  
reduction from 
admission  
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to discharge of 
brain natriuretic 
peptide and N-
terminal  
prohormone brain 
natriuretic peptide 
in these patients  
is a predictor of 
future 
cardiovascular 
events 
 
Feola, M., Testa, 
M., Leto, L., 
Cardone, M., Sola, 
M., & Rosso, G. L. 
(2016). Role of 
galectin-3 and 
plasma B type-
natriuretic peptide 
in predicting 
prognosis in 
discharged chronic 
heart failure 
patients. Medicine, 
95(26), e4014. 
http://doi.org/10.
None Design: Non- 
experimental 
-RCT 
-Level 2 
evidence 
purpose-
analyze value of 
pre-discharged 
determination 
of plasma 
galectin-3 
alone/with 
BNP in 
predicting mid-
term outcome 
in frequent-
N=83 patients 
Setting: All 
chronic HF 
subjects 
discharged 
after an acute 
episode of 
cardiac 
decompensati
on were 
enrolled in an 
out-patient 
clinic 
follow-up. 
-13 cardiac 
deaths, 35 
Variables: 
Event(cardiac 
death or 
rehospitalizati
on) 
Frequent 
flyer- 
hospitalized > 
or equal to 2 
times/year 
Event group- 
(frequent 
flyer and 
cardiac death) 
IV1=BNP IV2: 
Galectin-3 
BNP: Is it a pre-
discharge 
determinant? 
Galectin-3: 
Does this make 
a stronger 
predictor when 
added to BNP? 
Midterm 
outcome of 
readmission: 
approximately 
18 months 
Kaplan–
Meier 
curves  
Shapiro–
Wilk test 
Spearman 
coefficient 
(rho) 
- Shapiro–
Wilk test 
was used to 
evaluate 
whether or 
not the 
distribution 
of the 
variables was 
normal 
-negative 
Spearman 
coefficient 
(rho) of 
−0.38 
indicates a 
-Limitations: small 
sample size 
observed that 
might reduce the 
power of some 
consolidated 
prognostic 
parameters and 
did not permit a 
correct distinction 
between HFrEF 
and HFpEF 
Strength: easy and 
practical 
prognostic 
parameters able 
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000004014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
flyers (FF) HF (≥
2 hospitalization 
for 
HF/year)/dead 
patients 
discharged after 
an acute 
decompensated 
HF (ADHF) 
episode 
rehospitalizati
ons 
Twenty-eight 
HF patients 
were 
hospitalized 
≥2times/year 
(range 2–
4times/ 
year) and were 
defined FF (8 
patients out of 
28 died 
because of 
a cardiac 
death) 
-the group 
with a worst 
clinical 
prognosis 
(FF+cardiac 
death) was 
formed by 33 
patients 
(39.8%) is 
events group.  
DV=midterm 
outcome of 
readmission 
moderate 
decreasing 
monotonic 
trend 
between 
galectin-3 
and 
glomerular 
filtrate (P = 
0.0055), 
while a 
positive 
correlation 
(rho = 0.44, P 
= 0.002) 
between 
galectin-3 
and BNP was 
detected 
-Kaplan–
Meier curves 
depicted the 
powerful 
stratification 
using 
BNP + Gal-3 
in predicting 
clinical 
to predict adverse 
outcome are 
mandatory in 
order to allocate 
resources and 
establish tailoring 
specific follow-up.  
High level and 
quality of 
evidence. 
Conclusion:  
Galectin-3 + BNP is 
the strong 
predictive value of 
readmission 
Feasibility: 
This study looks at 
the predictive 
quality of plasma 
galectin-3 both 
alone and with 
BNP levels in 
determining 
readmission. It 
does answer the 
PICOT question.  
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Follow-up 
range: range 
4–22 months 
 
Average 
number of 
beds: NR 
Attrition: NR 
course at 
mid-term 
follow-up 
(log-rank 
5.65; P = 
0.017) 
 
Kilgore, M., Patel, 
H. K., Kielhorn, A., 
Maya, J. F., & 
Sharma, P. (2017, 
May 10). Economic 
burden of 
hospitalizations of 
Medicare 
beneficiaries with 
heart failure. Risk 
Management and 
Healthcare Policy, 
2017(10), 63-70. 
Retrieved from 
https://www.ncbi.
nlm.nih.gov/pmc/
articles/PMC54367
69/pdf/rmhp-10-
063.pdf 
None Retrospective 
Observational 
Study 
Level 5 
N=63,678 
patients 
Setting: 
Inpatient data 
were gathered 
for Medicare 
beneficiaries 
with at least 
one HF-related 
hospitalization 
between July 
1, 2005, and 
December 31, 
2011 
Variables: 
IV1- mean 
per-patient 
cost of an HF-
related 
hospitalizatio
n 
IV2- Cost of 
hospital 
readmission 
DV: Cost of 
care for HF 
patients. 
The cost of care 
for patients 
with HF 
diagnosis is 
substantial and 
readmissions 
add to the 
economic 
burden. 
 
Cost 
analysis 
The mean 
per-patient 
cost of an 
HF-related 
hospitalizatio
n was 
$14,631. 
22.3% of 
patients 
were 
readmitted 
within 30 
days, 33.3%  
were 
readmitted 
within 60 
days, and 
40.2% were 
readmitted 
Strengths:  
Limitations: 
unable to 
differentiate 
reliably between 
systolic and 
diastolic HF. The 
requirement for 
continuous 
enrollment during 
this period may 
have resulted in 
selection bias. 
readmission data 
excluded those 
who died.  
Conclusion: the 
costs associated 
with 
hospitalization in 
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within 90 
days. 
 
patients with HF 
are high. In  
addition, once 
patients are 
hospitalized for 
HF, they 
frequently require 
rehospitalization 
Feasibility: large, 
nationally 
representative 
sample of HF 
hospitalizations. 
Kociol, R. D., 
Horston, J. R., 
Fonarow, G. C., 
Reyes, E. M., 
Shaw, L. K., 
O'Connor, C. M., ... 
Hernandez, A. F. 
(2011). Admission, 
discharge, or 
change in b-type 
natriuretic peptide 
and long-term 
outcomes: Data 
from organized 
program to initiate 
None Design: 
Retrospective 
Cohort study 
Level 2 
evidence 
N=Patients 
7039  
Setting: 
patients in 220 
hospitals. 65 
years of age 
from hospitals 
in Organized 
Program to 
Initiate 
Lifesaving 
Treatment in 
Hospitalized 
Patients with 
Heart Failure 
Variables: 
IV1- 
Admission 
value of BNP. 
IV2- the ratio 
of admission 
to discharge 
BNP. 
IV3- The 
discharge 
value of BNP.  
DV- Post-
discharge 
prognosis. 
Is admission, 
discharge, or 
change from 
admission to 
discharge BNP 
measure is the 
most important 
predictor of 
long-term 
outcomes? 
 
Cox 
proportio
nal 
hazards 
regression 
models 
The 
discharge 
BNP model 
improved 
risk 
reclassificati
on and 
discriminatio
n in 
predicting 
each 
outcome.  
 
Strengths: 
Multiple 
outcomes can be 
measured. Real 
world 
variables and 
outcomes  
were measured. 
Limitations: There 
is potential for 
unmeasured or 
residual 
confounding. The 
analysis was 
restricted to older 
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lifesaving 
treatment in 
hospitalized 
patients with heart 
failure (OPTIMIZE-
HF) linked to 
Medicare claims. 
Circulation Heart 
Failure, 4, 628-
636. 
http://dx.doi.org/1
0.1161/CIRCHEART
FAILURE.111.9622
90 
(OPTIMIZE-HF) 
to Medicare 
claims.  
 
patients enrolled 
in 
Medicare fee-for-
service, hence the 
results may not be 
gen- 
eralizable to 
younger HF 
patients. 
Feasibility: The 
addition of 
discharge BNP to 
clinical 
variables modestly 
improves risk 
classification and 
model 
discrimination for 
long-term 
outcomes 
 
Conclusion: The 
model with 
clinical variables 
plus discharge 
BNP also 
appropriately 
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reclassifies 
patients among 
tertiles of risk and 
improves 
discrimination 
compared with a 
model with clinical 
variables 
alone. Further 
research is needed 
to test the role 
that these 
prognostic models 
could play in 
improving 
postdischarge 
treatment and 
outcomes for HF 
patients. 
 
 
Leto, L., Testa, M., 
& Feola, M. 
(2015). Correlation 
between B-Type 
Natriuretic Peptide 
and 
Functional/Cogniti
None Design: Non-
experimental  
-Cohort study 
-Level 3 
evidence 
Purpose: the 
role of BNP 
N= 951 
patients 
recorded 
between 
2011-2014. 
403 had BNP 
at discharge 
IV: BNP levels 
DV1: 
mortality 
DV2: 6-month 
readmission 
Variables:  
BNP levels: 
Does BNP guide 
HF therapy? 
Mortality: Is 
admission or 
pre-discharge 
BNP more 
-Pearson’s 
correlatio
n 
coefficient 
-Two 
sample t-
test 
Pearson’s 
correlation 
coefficient 
was 
calculated to 
describe the 
linear 
Limitations: Only 
37% were female. 
Strengths: 
Number of 
patients in sample 
size. Correlation 
between BNP and 
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ve Parameters in 
Discharged 
Congestive Heart 
Failure Patients. 
International 
Journal Of 
Endocrinology, 
20151-7. 
doi:10.1155/2015/
239136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
determination 
and association 
with a major 
outcome such 
as mortality or 
readmission 
after a 6-month 
period of 
follow-up 
Setting: 
Consecutive 
patients 
admitted to 
our unit with 
symptoms of 
acute HF or 
worsening of 
chronic HF 
were asked to 
enter the 
study  
Looked at 
mortality/6-
month 
readmission 
rate 
 
Follow up: 6 
months 
 
Attrition: NR 
Heart Failure 
defined as 
two major 
criteria and 1 
major 
criterion and 
2 minor 
criteria of 
Framingham 
classification  
predictive of 
mortality in HF? 
Readmission:  
Does BNP 
predict hospital 
readmission 
within 6 
months? 
-Pearson’s 
Chi-
square 
test 
correlation 
between 
BNP levels 
and multiple 
parameters 
 
Comparison 
between 
different 
means in the 
two BNP 
groups was 
verified 
through the 
independent 
two-sample 
𝑡-test 
(Student’s 𝑡-
test) 
 
Pearson’s 
Chi-square 
test was 
used to 
evaluate the 
association 
between 
BNP levels 
multiple factors 
were analyzed.  
Conclusion: higher 
BNP levels are 
linked with a 
worse prognosis in 
terms of mortality 
and readmission 
at 6 months. 
 
Feasibility: This 
study 
differentiates 
between 
admission and 
pre-discharge BNP 
as a predictor of 
outcome. It does 
answer the PICOT 
question. 
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 and 
categorical 
outcome 
variables 
(mortality, 
hospital 
readmission) 
 
Logeart, D., 
Thabut, G., 
Jourdain, P., 
Chevelas, C., 
Beyne, P., 
Beauvais, F., & ... 
Solal, A. C. (2004). 
Predischarge B-
type natriuretic 
peptide assay for 
identifying 
patients at high 
risk of re-
admission after 
decompensated 
heart failure. 
Journal Of The 
American College 
Of Cardiology 
None Design: Non-
experimental 
-Cohort study 
-Level 3 
evidence 
Purpose: Aim is 
to determine 
the value of 
BNP versus 
clinical variables 
for predicting 
the post-
discharge 
outcome of 
patients 
admitted for HF 
 
N= 127 
patients 
enrolled and 
13 excluded- 
this left 114 in 
derivation 
study. 109 
from another 
center were in 
the validation 
study 
Setting: single 
hospital 
setting 
Follow up: 6 
months 
Attrition: 
Derivation 
study- 13 
excluded for 
IV1: serial/ 
pre-discharge 
BNP 
IV2: pre-
discharge 
Echocardiogra
m 
IV3: clinical 
variables 
DV1: early 
death 
DV2: 
readmission 
 
Variables: 
Serial BNP 
studied from 
admit to 
discharge 
Serial/pre-
discharge BNP: 
Do serial/pre-
discharge BNP 
levels have 
significance in 
determining 
predicting early 
death and 
readmission?  
Pre-discharge 
echocardiogra
m: Is LVEF vs 
Doppler mitral 
patterns on a 
pre-discharge 
echo a better 
indicator of 
death and/or 
readmission? 
-Newman-
Keuls 
post hoc 
test 
-Cox 
proportio
nal 
hazards 
regression 
Models 
 
- Group 
comparisons 
of BNP 
values were 
made by 
using 
analysis of 
variance with 
the 
Newman-
Keuls 
post hoc test 
-Cox 
proportional 
hazards 
regression 
models to 
examine the 
relation of 
clinical 
Limitations: Study 
population was 
not large. 
Outcomes 
determined by 
patient could be 
subjective. 
Strengths: 2 
hospital sites 
used. Discharge 
decided by 2 
senior 
cardiologists in 
charge of HF unit 
using multiple 
criteria. 
Outcome 
determined by the 
practitioner.  
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(JACC), 43(4), 635-
641. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
emergent 
transplantatio
n, transfer to 
another 
hospital, the 
absence of 
predischarge 
BNP 
measurements
, or rectified 
non-CHF 
diagnosis. 
- pre-
discharge 
Doppler 
mitral pattern 
- clinical 
variables and 
left 
ventricular 
ejection 
fraction 
 
Readmission 
is defined by 
hospitalizatio
n for 
decompensat
ed HF. 
Endpoint 
combined 
death or first 
unscheduled 
readmission 
for HF.  
Clinical 
Variables: Do 
clinical 
variables have a 
strong 
association in 
predicting early 
death and 
readmission? 
Early death: Is 
pre-discharge 
BNP, pre-
discharge echo 
or clinical 
variables the 
best indicator 
of early death? 
Readmission: Is 
pre-discharge 
BNP, pre-
discharge echo 
or clinical 
variables the 
best indicator 
of readmission? 
 
 
variables, 
BNP 
levels, and 
echo findings 
with the 
incidence of 
primary 
endpoint 
(death or re-
admission 
for CHF) or 
alone 
re-admission 
for CHF 
within the 
first month 
and at six 
months after 
discharge 
Conclusion: High 
pre-discharge BNP 
assay is a strong, 
independent 
marker of death 
or re-admission 
after 
decompensated 
HF. It is more 
relevant than 
common clinical 
or 
echocardiographic 
parameters 
and more relevant 
than changes in 
BNP levels during 
acute cares. 
Feasibility: This 
study evaluates 
pre-discharge BNP 
and clinical 
variables as 
predictors of 
readmission or 
death. It does 
answer the PICOT 
question. 
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Lourenco, P., 
Ribeiro, A., 
Pintalhao, M., 
Silva, S., & 
Bettencourt, P. 
(2015). Predictors 
of six-month 
mortality in BNP-
matched acute 
heart failure 
patients. American 
Journal of 
Cardiology, 116, 
744-748. 
http://dx.doi.org/1
0.1016/j.amjcard.2
015.05.046 
 
None Design: Case-
control study 
Level 4 
evidence 
N=224 
patients with 
112 surviving 
and 112 not 
surviving a 6-
month period. 
Setting: 
Prospectively 
recruited 
population of 
hospital 
recruited 
patients with 
HF diagnosis, 
with a 
retrospective 
convenience 
sample.  
Variables: 
IV1- BNP; IV2- 
Prognostic 
predictors.  
DV- mortality 
Prognostic 
predictors: 
admission HR, 
admission SBP, 
HGB, plasma 
urea.  
Median time to 
death- 69 days. 
Cox 
regression 
analysis 
In BNP 
matched 
patients with 
acute HF, the 
only 
independent 
mortality 
predictor is 
BNP 
decrease. 
Strengths: Less 
costly and less 
time-consuming.  
Limitations: 
single-center 
study. 
Generalizability 
concerns. It was a 
convenience 
sample and 
possibly not 
representative.  
Feasibility: 
Feasible to use 
BNP as a predictor 
of outcomes. 
Conclusion: Study 
reinforces BNP as 
the gold standard 
for HF prognostic 
prediction. 
Magnussen, C., & 
Blankenberg, S. 
(2018). Biomarkers 
for heart failure: 
small molecules 
with high clinical 
relevance. The 
None Design: 
Literature 
review 
Level 5 
evidence 
N= N/A 
Setting: HF 
patients with 
biomarkers 
drawn. 
IV1- BNP 
biomarkers; 
IV2- Troponin 
biomarkers; 
IV3- C-
reactive 
protein 
None None An 
investigation 
of BNP, 
troponin, 
and next-
generation 
biomarkers 
Strengths: 
Multiple article 
results included.  
Limitations: 
Reliance on the 
available research 
published. 
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Association for the 
Publication of the 
Journal of Internal 
Medicine, 283, 
530-543. 
http://dx.doi.org/1
0.1111/joim.12756 
 
biomarkers; 
IV4- next-
generation 
biomarkers.  
DV- Best 
predictor of 
HF mortality 
and 
readmission.  
to predict 
mortality 
and 
readmission.  
Because of 
their 
noninvasive 
determinatio
n with 
mostly high 
sensi- 
tivity and 
accuracy, 
circulating 
blood 
biomarkers 
are 
becoming 
increasingly 
important 
for daily 
clinical 
practice.  
 
Feasibility: 
Conclusion: 
Multimarker 
approaches 
containing 
different 
combinations of 
established and 
novel biomarkers 
might improve 
HF risk prediction 
at the population 
level once they 
are used on top of 
clinical variables. 
Only BNP, Nt-
proBNP and MR-
proANP 
should be used in 
the context of HF 
diagnosis, 
prognosis and – in 
part – therapy 
monitoring. 
 
 
Mozaffarian, D., 
Benjamin, E. J., Go, 
None Design: Meta-
analysis 
N=N/A None None None The 
American 
Strengths: Data 
from multiple 
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A. S., Arnett, D. K., 
Blaha, M. J., 
Cushman, M., ... 
Turner, M. B. 
(2015, December 
16). Heart disease 
and stroke 
statistics—2016 
update. 
Circulation, 
137(25), 1-323. 
http://dx.doi.org/1
0.1161/CIR.00000
00000000350 
 
Level 1 
evidence 
Setting: The 
AHA works 
with the CDC’s 
NCHS, the 
NHLBI, the  
NINDS, and 
other 
government 
agencies to 
derive the 
annual  
statistics in 
this Heart 
Disease and 
Stroke 
Statistical 
Update.  
 
Heart 
Association 
(AHA), in 
con- 
junction with 
the Centers 
for Disease 
Control and 
Prevention,  
the National 
Institutes of 
Health, and 
other 
government 
agen- 
cies, brings 
together the 
most up-to-
date 
statistics 
related to  
heart 
disease, 
stroke, and 
other 
cardiovascul
ar and 
metabolic  
articles and 
reference sites. 
Limitations: Not 
including some 
articles can lead to 
bias. 
Feasibility: These 
articles can guide 
treatments and 
therapies for 
these disease 
processes. 
Conclusion: This 
analysis 
continuously  
monitors and 
evaluates sources 
of data on heart 
disease and  
stroke in the 
United States to 
provide the most 
current 
information 
available in the 
Statistical Update.  
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diseases and 
presents 
them in its 
Heart 
Disease and 
Stroke  
Statistical 
Update.  
 
O'Connor, C. M. 
(2017, May 5). 
High heart failure 
readmission rates: 
Is it the health 
system’s fault? 
Journal of 
American College 
of Cardiology, 5(5). 
http://dx.doi.org/1
0.1016/j.jchf.2017.
03.011 
 
None Design: Expert 
Opinion 
Level 5 
evidence 
 
Setting: HF 
patients 
None None None The length of 
stay and the 
degree of 
decongestio
n are 
important 
components 
of 
readmission 
risk. If you 
want to 
reduce your 
30-day 
readmission 
rate, keep 
your patient 
in the 
hospital 
longer. 
Limitations: Only 
opinions. 
Strengths: 
Experience of 
experts. 
Feasibility:  
Conclusion: The 
organization of 
the care in these 
facilities is 
complex and 
sometimes not 
coordinated with 
the health system; 
thus it is the 
health system that 
can best optimize 
care. 
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Schreiber, D. 
(2016). Natriuretic 
Peptides in 
Congestive Heart 
Failure. Retrieved 
from 
http://emedicine.
medscape.com/art
icle/761722-
overview#a3 
 
None Design: Expert 
opinion 
Level 5 
N= N/A 
Setting: 
Patients with 
HF diagnosis 
with BNP 
levels drawn. 
None None None Recommend
ations were 
made for the 
use of BNP in 
clinical 
practice.  
Limitations: Only 
opinions. 
Strengths: 
Experience of 
experts. 
Feasibility: BNP 
can be used to 
diagnose varying 
disease process 
and to predict 
many outcomes. 
Conclusions: BNP 
levels of less than 
100pg/mL and of 
more than 
500pg/mL have a 
90% negative 
predictive value 
(NPV) and positive 
predictive value 
(PPV), 
respectively, for 
the diagnosis of 
congestive heart 
failure (CHF) in 
patients 
presenting with 
acute dyspnea. 
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Stuart, C. (2014, 
April 18). Heart 
failure stands out 
for costly 
readmissions. 
Cardiovascular 
Business. 
Retrieved from 
http://www.cardio
vascularbusiness.c
om/topics/heart-
failure/heart-
failure-stands-out-
costly-
readmissions 
 
None Design: Expert 
opinion 
Level 5 
N= N/A 
Setting: 30-
day 
readmission 
with HF 
diagnosis.  
None None None Congestive 
heart failure 
took the 
biggest 
chunk of the 
Medicare 
readmission 
budget, at 
7.3 percent 
of total costs 
Limitations: Only 
opinions. 
Strengths: 
Experience of 
experts. 
Conclusion: CHF 
ranked seventh 
for Medicaid 
readmissions 
(18,800 
rehospitalizations 
at a cost of $273 
million) and eighth 
for uninsured 
readmissions 
(3,600 and $43 
million). 
Wettersten, N., & 
Maisel, A. S. 
(2016). Biomarkers 
for heart failure: 
An update for 
practitioners of 
internal medicine. 
The American 
Journal of 
Medicine, 129, 
560-567. 
None Design: Case 
Report 
Level 5 
evidence 
 
N= N/A 
Setting: 70-
year-old 
woman with a 
history of HF. 
IV1- 
Natriuretic 
Peptides; IV2- 
Troponin; IV3- 
sST2; IV4- 
Procalcitonin 
None None The NPs are 
regularly 
ordered in 
patients 
presenting 
with acute 
heart failure, 
but their full 
potential is 
often 
Strengths: 
Limitations: 
Feasibility: 
Conclusion: 
Natriuretic 
Peptides are aids 
for diagnosis and 
management and 
must be 
interpreted within 
their clinical 
PRE-DISCHARGE BNP: A PROTOCOL CHANGE TO REDUCE 64 
 
 
http://dx.doi.org/1
0.1016/j.amjmed.2
016.01.013 
 
underutilized
. 
 
context and not 
solely acted upon. 
Yancy, C. W., 
Jessup, M., 
Bozkurt, B., Butler, 
J., Casey, D. E., 
Colvin, M. M., ... 
Westlake, C. 
(2017, September 
5, 2017). 2017 
ACC/AHA/HFSA 
Focused Update of 
the 2013 
ACCF/AHA 
Guideline for the 
Management of 
Heart Failure: A 
Report of the 
American College 
of 
Cardiology/Americ
an Heart 
Association Task 
Force on Clinical 
Practice Guidelines 
and the Heart 
None Design: 
Evidence-based 
clinical practice 
guidelines 
Level 1 
evidence 
Setting: HF 
patients 
IV- Pre-
discharge BNP  
DV- post-
discharge 
prognosis.  
None None Pre-
discharge 
natriuretic 
peptide 
biomarker 
levels and 
the relative 
change in 
levels during 
hospital 
treatment 
are strong 
predictors of 
the risk of 
death or 
hospital  
readmission 
for HF. 
Strengths: expert 
opinion of AHA 
committee 
members. 
Observational and 
retrospective 
studies were 
utilized. 
Limitations: 
Increased risk of 
bias.  
Feasibility: This 
guideline uses 
evidence-based 
studies to guide 
treatment. 
Conclusion: 
Although 
observational or 
retrospective 
studies have 
suggested that 
patients  
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Failure Society of 
America. 
Circulation, 
136(10). 
http://dx.doi.org/1
0.1161/CIR.00000
00000000509 
with natriuretic 
peptide biomarker 
reduction had 
better outcomes 
than those 
without any 
changes or with a 
biomarker rise, 
targeting a certain  
threshold, value, 
or relative change 
in these biomarker 
levels during 
hospitalization 
may not be 
practical or safe 
for every patient 
and has not been 
tested in a  
prospective large-
scale trial.  
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Appendix B 
Rogers’ Diffusion of Innovation Theory: Decision-Innovation Process 
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Appendix C 
 
Rogers’ Diffusion of Innovation Theory: Adopter Categories 
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Appendix D 
Proposed Pre-Discharge BNP Protocol 
A pre-discharge BNP should be drawn on all patients with a primary or secondary diagnosis of  
HF within 24-48 hours prior to discharge and reported to the patient care provider. A  
recommendation of <450 pg/ml should be met before the patient is discharged. 
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Appendix E 
Retrospective Chart Audit Tool for Needs Assessment 
Number of 
participants 
Date 
admitted 
Date 
discharged 
Date last BNP 
drawn pre-
discharge 
Numeric 
value of 
last BNP 
level 
collected 
Date 
readmitted 
Numeric value of 
BNP on 
readmission 
1 9/22/18 10/5/18 10/4/18 898 10/6/18 2357 
2 10/1/18 10/10/18 10/10/18 538 10/12/18 693 
3 10/1/18 10/4/18 10/3/18 778 10/28/18 374 
4 10/13/18 10/17/18 10/17/18 470 11/9/18 >3433 
5 10/15/18 10/18/18 10/17/18 1295 10/25/18 1431 
6 10/16/18 10/24/18 10/19/18 1214 10/25/18 1538 
7 10/19/18 10/22/18 10/22/18 569 10/29/18 723 
8 10/19/18 10/22/18 10/20/18 700 10/27/18 882 
9 10/19/18 10/23/18 10/22/18 669 11/8/18 778 
10 10/21/18 11/7/18 11/2/18 386 11/26/18 814 
11 10/22/18 10/26/18 10/25/18 2594 10/29/18 1796 
12 10/25/18 11/3/18 10/31/18 578 11/22/18 175 
13 10/28/18 11/5/18 11/5/18 457 11/6/18 777 
14 11/10/18 11/14/18 11/13/18 79 12/6/18 383 
15 11/11/18 11/20/18 11/16/18 906 11/27/18 2344 
16 11/14/18 11/16/18 11/16/18 554 12/6/18 1514 
17 11/16/18 11/21/18 11/21/18 897 12/20/18 1080 
18 11/25/18 11/28/18 11/27/18 408 12/6/18 1127 
19 12/3/18 12/6/148 12/3/18 2254 12/10/18 3391 
20 12/3/18 12/10/18 12/8/18 887 12/14/18 1606 
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Appendix F 
Data Collection Tool Post-Policy Implementation 
Number of 
participants 
Admit 
Date 
Admit 
BNP 
Pre-
discharge 
Date BNP 
Drawn 
Pre-
discharge  
BNP 
24-48 H 
of pre-
discharge 
Greater 
than 48 
H pre-
discharge 
D/C 
date  
Attending 
physician/ 
physician 
group 
Readmit 
within 
30 days 
1.  1/8 775 1/10 593 Y N 1/11 A Y 
2.  1/12 1581 1/19 601 Y N 1/19 B N 
3.  1/13 565 1/15 399 Y N 1/15 A Y 
4.  1/13 >3433 1/15 >3433 Y N 1/15 B Y 
5.  1/14 2296 1/18 1869 Y N 1/19 B Y 
6.  1/16 758 1/21 1110 Y N 1/21 B Y 
7.  1/18 2292 1/22 1013 N Y 1/25 B Y 
8.  1/18 1010 1/22 744 N Y 1/22 B Y 
9.  1/18 >3433 1/25 >3433 Y N 1/25 B Y 
10.  1/25 2586 1/29 732 Y N 1/29 B N 
11.  1/27 242 1/28 248 Y N 1/30 B N 
12.  1/28 733 1/28 Not done N Y 2/1 B Y 
13.  1/29 >3433 2/5 2903 Y N 2/7 B N 
14.  1/30 103 2/5 104 Y N 2/5 B N 
15.  1/30 1448 2/4 74 Y N 2/4 B N 
16.  1/31 942 2/5 714 Y N 2/5 B N 
17.  2/1 682 2/4 668 Y N 2/5 B N 
18.  2/1 1025 2/5 818 N Y 2/8 A Y 
19.  2/2 1055 2/4 956 Y N 2/6 B N 
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20.  2/2 1025 2/5 818 N Y 2/8 A Y 
21.  2/3 1563 2/7 501 Y N 2/7 B Y 
22.  2/3 1354 2/13 2962 Y N 2/13 B Y 
23.  2/4 815 2/9 132 Y N 2/10 B N 
24.  2/4 105 2/8 64 N Y 2/14 B N 
25.  2/9 656 2/11 636 Y N 2/13 B Y 
26.  2/9 450 2/13 359 Y N 2/13 B Y 
27.  2/10 2225 2/13 1192 Y N 2/14 B Y 
28.  2/11 1683 2/22 777 Y N 2/22 B N 
29.  2/11 Not 
drawn 
2/13 184 Y N 2/14 B N 
30.  2/11 296 2/28 71 Y N 2/28 B N 
31.  2/12 1221 2/15 911 Y N 2/15 B N 
32.  2/13 2668 3/13 1417 Y N 3/14 B N 
33.  2/13 3400 2/15 3322 Y N 2/15 A Y 
34.  2/17 1090 2/20 569 Y N 2/22 B N 
35.  2/18 975 2/21 946.7 Y N 2/22 A Y 
36.  2/25 924 2/27 922 Y N 2/27 B N 
37.  2/27 922 2/28 922.3 Y N 3/1 B N 
38.  3/2 2245 3/6 1036 Y N 3/7 B N 
39.  3/2 1550 3/5 1329 Y N 3/6 B Y 
40.  3/3 744 3/5 201 Y N 3/5 B N 
41.  3/4 138 3/11 233 Y N 3/11 B N 
42.  3/10 >3433 3/18 440 Y N 3/18 B N 
43.  3/10 1671 3/15 581 N Y 3/18 B N 
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44.  3/11 >3433 3/15 2010 Y N 3/15 B N 
45.  3/12 1649 3/25 1810 Y N 3/25 B N 
46.  3/12 1850 4/1 1876 Y N 4/1 D Y 
47.  3/15 841 3/16 670 N Y 3/20 B N 
48.  3/15 635 3/22 546 Y N 3/22 C Y 
49.  3/16 554 3/18 949 Y N 3/20 B N 
50.  3/16 125 3/27 42 Y N 3/27 C Y 
51.  3/17 950 3/20 279 Y N 3/20 A Y 
52.  3/18 574 3/31 432 Y N 4/2 B N 
53.  3/18 1955 3/26 1290 Y N 3/26 A Y 
54.  3/19 1088 3/20 1012 Y N 3/20 B N 
55.  3/19 377 3/21 161 Y N 3/21 B N 
56.  3/21 178 3/28 119 Y N 3/29 B N 
57.  3/21 1651 3/24 438 Y N 3/25 B N 
58.           
59.           
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Appendix G 
 
Timeline for Project Implementation 
 
Months & Years Tasks to Accomplish 
July & August 2018 Contact the Director of Nursing to discuss the DNP 
project plan. 
Obtain permission for the project from the CNO. 
Data collection of project information to present to 
CNO and CQO completed. 
September & October 2018 Completion of IRB proposal to JSU IRB board. 
Await IRB approval. 
Meet with the Chief Quality Officer to discuss the 
collection of data and evidence to support a BNP 
policy change. 
 
November & December 2018 Identify and categorize adopters within the facility. 
Permission obtained for regional cardiology group 
to participate in project through implementation of 
pre-discharge BNP draws on their HF patients which 
meet criteria. 
Literature review presented to the CQO and 
regional cardiology group to support the needed 
protocol change. 
Data collection for needs assessment through a 
retrospective chart audit completed. 
Proposed protocol composed through 
interprofessional collaboration with CQO. 
 
January & February 2019 Implementation of the protocol through the 
regional cardiology group. 
Data collected during post-implementation time 
period on patients from regional cardiology group 
and other discharged HF patients. 
 
March & April 2019 Continued implementation of the protocol through 
the regional cardiology group. 
Continue data collection during post-
implementation time period on patients from 
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regional cardiology group and other discharged HF 
patients. 
Committee meetings to report evidence of protocol 
effectiveness from post-implementation data 
collected.  
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Appendix H 
Statistical Contour Plots 
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Appendix I 
Statistical Main Effects Plot 
 
 
 
 
 
 
 
 
